94. Primary sclerosing cholangitis Clinical trials / Disease details
Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00953615 (ClinicalTrials.gov) | April 2006 | 4/8/2009 | Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC) | Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | Drug: Thalidomide | Mayo Clinic | Celgene Corporation | Terminated | 18 Years | 72 Years | All | 1 | Phase 2 | United States |